Erratum to "Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis" [Leukemia Research 32 (2008) 1279-1287] (DOI:10.1016/j.leukres.2007.12.018);Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis

Leukemia Research

Volumn 32, Issue 8, 2008, Pages 1279-1287

  El Hajj Dib, Iman ^a   Mélanie, Gressier ^a   Valery, Salle ^b   Romuald, Mentaverri ^a,c   Michel, Brazier ^a,b,c   Kamel, Saïd ^a,b,c  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Apoptosis; Bone resorption; Imatinib; M CSF; Multiple myeloma; Osteoclast

Indexed keywords

COLONY STIMULATING FACTOR 1; IMATINIB; INTERLEUKIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 42749085995     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.004     Document Type: Erratum

References (40)

1. R. Bataille J.L. Harousseau Multiple myeloma N Engl J Med 336 1997 1657 1664
2. S. Barille-Nion B. Barlogie R. Bataille P.L. Bergsagel J. Epstein R.G. Fenton Advances in biology and therapy of multiple myeloma Hematology 2003 248 278
3. E. Terpos M.A. Dimopoulos Myeloma bone disease: pathophysiology and management Ann Oncol 16 2005 1223 1231
4. A. Valentin-Opran S.A. Charbon P.J. Meunier C.M. Edouard M.E. Arlot Quantitative histology of myeloma-induced bone changes Br J Haematol 52 1982 601 610
5. R. Bataille D. Chappard C. Marcelli P. Dessauw P. Baldet J. Sany Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma J Clin Invest 88 1991 62 66
6. S.J. Choi F. Cruz H. Craig H. Chung R.D. Devlin G.D. Roodman Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood 96 2000 671 675
7. M. Abe K. Hiura J. Wilde K. Moriyama T. Hashimoto S. Ozaki Role for Macrophage inflammatory protein (MIP)1-alpha and MIP 1-beta in the development of osteolytic lesions in multiple myeloma Blood 100 2002 2195 2202
8. A.C.W. Zanettino A.N. Farrugia A. Kortesidis J. Manavis L.B. To S.K. Martin Elevated serum levels of stromal-derived factor-1 α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients Cancer Res 65 2005 1700 1709
9. S.K. Martin A.L. Dewar A.N. Farrugia N. Horvath S. Gronthos L.B. To Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma Clin Cancer Res 12 2006 6973 6977
10. X. Yu Y. Huang P. Collin-Osdoby P. Osdoby Stromal cell-derived factor-1 (SDF-1) recruits osteoclasts precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration J Bone Miner Res 18 2003 1404 1418
11. L.M. Wright W. Maloney X. Yu L. Kindle P. Collin-Osdoby P. Osdoby Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promote the chemotactic recruitment, development and survival of human osteoclasts Bone 36 2005 840 853
12. D.E. Hughes K.R. Wright H.L. Uy A. Sasaki T. Yoneda G.D. Roodman Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo J Bone Miner Res 10 1995 1478 1487
13. A.M. Parfitt G.R. Mundy G.D. Roodman D.E. Hughes B.F. Boyce A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates J Bone Miner Res 11 1996 150 159
14. A.A. Reszka J.M. Halasy-Nagy P.J. Masarachia G.A. Rodan Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase J Biol Chem 274 1999 34967 34973
15. T. Kameda H. Mano T. Yuasa Y. Mori K. Miyazawa M. Shiokawa Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts J Exp Med 186 1997 489 495
16. K. Fuller J.M. Owens C.J. Jagger A. Wilson R. Moss T.J. Chambers Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts J Exp Med 178 1993 1733 1744
17. E. Jimi T. Shuto T. Koga Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells Endocrinology 136 1995 808 811
18. K. Tezuka T. Sato H. Kamioka P.J. Nijweide K. Tanaka T. Matsuo Identification of osteopontin in isolated rabbit osteoclasts Biochem Biophys Res Commun 186 1992 911 917
19. T. Kameda T. Ishikawa T. Tsutsui Detection and characterization of apoptosis in osteoclasts in vitro Biochem Biophys Res Commun 207 1995 753 760
20. R.N. Pearse E.M. Sordillo S. Yaccoby B.R. Wong D.F. Liau N. Colman Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proc Natl Acad Sci 98 2001 11581 11586
21. N. Giuliani R. Bataille C. Mancini M. Lazzaretti S. Barille Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment Blood 98 2001 3527 3533
22. N. Giuliani S. Colla R. Sala M. Moroni M. Lazzaretti S. La Monica Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease Blood 100 2002 4615 4621
23. U. Heider C. Langelotz C. Jakob I. Zavrski C. Fleissner J. Eucker Expression of receptor activator of nuclear factor-κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma Clin Cancer Res 9 2003 1346 1440
24. A.N. Farrugia G.J. Atkins B.L. To B. Pan N. Horvath P. Kostakis Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo Cancer Res 63 2003 5348 5445
25. S.C. Manolagas Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 21 2000 115 137
26. E. Jimi S. Akiyama T. Tsurukai N. Okahashi K. Kobayashi N. Udagawa Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function J Immunol 163 1999 434 442
27. H. Glantschnig J.E. Fisher G. Wesolowski G.A. Rodan A.A. Reszka M-CSF, TNF alpha and RANK ligand promote osteoclast survival by signalling through mTOR/S6 kinase Cell Death Differ 10 2003 1165 1177
28. M. Nakamura S. Merchav A. Carter T.J. Ernst G.D. Demetri Y. Furukawa Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells J Immunol 143 1989 3543 3547
29. R.P. Gooding A. Bybee F. Cooke A. Little S.G. Marsh E. Coelho Apperley. Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia Br J Haematol 106 1999 669 681
30. M. Nakagawa T. Kaneda T. Arakawa S. Morita T. Sato T. Yomada Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts FEBS Lett 473 2000 161 164
31. M. Gallet N. Sévenet C. Dupont M. Brazier S. Kamel Breast cancer cell line MDA-MB-231 exerts a potent and direct anti-apoptotic effect on mature osteoclasts Biochem Biophys Res Commun 319 2004 690 696
32. M. Gallet R. Mentaverri N. Sevenet M. Brazier S. Kamel Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor Apoptosis 11 2006 1909 1921
33. A.L. Dewar K.V. Doherty T.P. Hughes A.B. Lyons Imatinib inhibits the functional capacity of cultured human monocytes Immunol Cell Biol 83 2005 48 56
34. A.L. Dewar A.C. Cambareri A.C. Zannettino B.L. Miller K.V. Doherty T.P. Hughes Macrophage colony-stimulating factor receptor c-FMS is a novel target of imatinib Blood 105 2005 3127 3132
35. J.R. Taylor N. Brownlow J. Domin N.J. Dibb FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance Oncogene 25 2006 147 151
36. W. Hofstetter A. Wetterwald M.C. Cecchini R. Felix H. Fleisch C. Mueller Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-FMS, in murine osteoclasts Proc Natl Acad Sci USA 89 1992 9637 9641
37. ®) enhances mature osteoclasts apoptosis and suppresses osteoclasts bone resorbing activity Eur J Pharmacol 3 551 1–3 2006 27 33
38. A.L. Dewar A.N. Farrugia M.R. Condina L. Bik To T.P. Hughes B. Vernon-Roberts Imatinib as a potential antiresorptive therapy for bone disease Blood 107 2006 4334 4337
39. E. Berman M. Nicolaides R.G. Maki M. Fleisher S. Chanel K. Scheu Altered bone and mineral metabolism in patients receiving imatinib mesylate N Engl J Med 354 2006 2006 2013
40. H. Ohno K. Kubo H. Murooka Y. Kobayashi T. Nishitoba M. Shibuya A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model Mol Cancer Ther 5 2006 2634 2643